This study will evaluate the effect of GS-5806 on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI), the effect of GS-5806 on being free of any supplemental oxygen, and rates of respiratory failure and… Read more »
GVAX vs. Placebo for MDS/AML After Allo HSCT
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether the intervention, in this case, the GVAX vaccine, works in preventing your MDS or AML from relapsing after your allogeneic stem cell transplantation. "Investigational" means that the… Read more »
MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
The study will evaluate the efficacy and safety of MK-8228 for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant. The hypothesis being tested is that MK-8228 is superior to placebo in the prevention of clinically-significant CMV infection through 24 weeks after transplant.
Ipilimumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplantation
This phase I trial studies the side effects and the best dose of ipilimumab in treating patients with relapsed hematologic malignancies after donor stem cell transplantation. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find… Read more »
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
The purpose of the study is to: – Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors – Assess the safety among NMDP donors of filgrastim administration and PBSC leukapheresis – Assess the safety and efficacy of filgrastim-mobilized… Read more »
National Marrow Donor Program Long-Term Donor Follow-Up
This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized peripheral blood stem cell (PBSC) donors. The primary goal is to evaluate the hypothesis that the incidence of targeted malignant, thrombotic and autoimmune disorders after unrelated hematopoietic stem cell donation are similar between unstimulated BM and filgrastim-mobilized PBSC… Read more »
Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity conditioning for subjects age 15-65 years with hematologic malignancies. A maximum of 60 eligible subjects will… Read more »
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
